Concepedia

Author

Gavin Giovannoni

Queen Mary University of London

Also Known As

C. Confavreux, Christian Confavreux, G Giovannoni, G. Giovannoni, Gavin Giovannoni, Giovannoni, G

87

Publications

5.1K

Citations

30

H-Index

28

Concepts

All Affiliations

Queen Mary University of LondonBiogen (United States)University Hospital of BaselCharles UniversitySt. Josef-Hospital
GG

About

Gavin Giovannoni is an author at Queen Mary University of London specializing in medicine, clinical trials, and multiple sclerosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

2.2K

2

Immunology

3

3

1.7K

3

Allergy

1

1

43

4

Allergy Medicine

1

1

43

5

Gastroenterology

1

1

60

Gavin Giovannoni

×

32

Publications

4.6K

Citations

28

H-Index

YearCitations

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold,

The Lancet

2012

1.2K

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson,

The Lancet Neurology

2009

470

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

David H. Miller, Derek Soon, Kryshani Fernando,

Neurology

2007

330

The incidence and significance of anti-natalizumab antibodies

Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux,

Neurology

2007

329

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj,

The Lancet

2013

285

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox,

Neurology

2017

273

Alemtuzumab CARE-MS I 5-year follow-up

Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen,

Neurology

2017

222

Health‐related quality of life in multiple sclerosis: effects of natalizumab

Richard A. Rudick, Deborah Miller, Steven Hass,

Annals of Neurology

2007

194

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

Grant Hill-Cawthorne, Tom Button, Orla Tuohy,

Journal of Neurology Neurosurgery & Psychiatry

2011

193

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Laura J. Balcer, Steven Galetta, Peter A. Calabresi,

Neurology

2007

128

Page 1